Goa Government Takes Strict Action Against Pharma Firm Over Suspected Counterfeit Snake Venom
The Goa government has made a decisive move to protect public health by blacklisting supplier and distributor M/s Arav Pharma. This firm stands accused of supplying spurious anti-snake venom to the state's health services. In a firm response, authorities have also decided to forfeit the earnest money deposit (EMD) submitted by the company.
Temporary Suspension of All Purchases
In addition to the blacklisting, the government has temporarily suspended all purchases from M/s Arav Pharma. This directive was communicated by the public health department to the directorate of health services. The public health department is responsible for procuring and supplying drugs to all health centres and district hospitals under its jurisdiction, making this suspension a critical step to prevent further distribution of potentially harmful medications.
Withdrawal of Suspected Counterfeit Batch
The action follows a complaint lodged last month, which prompted health services to withdraw a lyophilised batch of anti-snake venom suspected to be counterfeit. This batch had been received from Arav Pharma. Upon investigation, the supplier was issued a show cause notice, demanding an explanation for the alleged violations.
Legal Challenges and Court Ruling
M/s Arav Pharma challenged the show cause notice before the Bombay High Court, seeking relief in the form of quashing the notice. However, the court refused to grant this relief and instead directed the firm to respond to the notice as issued. This legal setback underscores the seriousness of the allegations and the government's commitment to enforcing regulatory standards.
Enhanced Verification Measures
To prevent similar incidents in the future, the public health department has instructed the directorate of health services to implement stricter verification protocols. Specifically, they must verify authorisation from manufacturers to distributors for the sale of drugs. This step aims to ascertain the authenticity of drugs supplied and avoid potential purchases of spurious or counterfeit medications, thereby safeguarding patient safety across Goa's healthcare facilities.
The government's swift action highlights its dedication to maintaining high standards in public health procurement and ensuring that only genuine, safe medications reach patients in need.
